Neuropeptides, dopamine, and schizophrenia

Charles Nemeroff, G. Bissette

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

In this paper, three types of evidence for the possible role of neuropeptides in the pathophysiology of schizophrenia are considered. First, studies in postmortem brain tissues and cerebrospinal fluid (CSF) have been conducted to determine whether the integrity or activity of neuropeptide-containing systems and their receptors is altered in schizophrenia. Second, studies in which peptides have been administered to schizophrenic patients to evaluate their potential therapeutic use are reviewed. Finally, the effects of peptide receptor antagonists on the symptoms of schizophrenic patients are reviewed.

Original languageEnglish
Pages (from-to)273-291
Number of pages19
JournalAnnals of the New York Academy of Sciences
Volume537
StatePublished - Dec 1 1988
Externally publishedYes

Fingerprint

Neuropeptides
Dopamine
Schizophrenia
Cerebrospinal fluid
Peptide Receptors
Therapeutic Uses
Cerebrospinal Fluid
Brain
Tissue
Peptides
Integrity
Antagonist
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Neuropeptides, dopamine, and schizophrenia. / Nemeroff, Charles; Bissette, G.

In: Annals of the New York Academy of Sciences, Vol. 537, 01.12.1988, p. 273-291.

Research output: Contribution to journalArticle

@article{9ba3e90614ce438b87b80da035e39966,
title = "Neuropeptides, dopamine, and schizophrenia",
abstract = "In this paper, three types of evidence for the possible role of neuropeptides in the pathophysiology of schizophrenia are considered. First, studies in postmortem brain tissues and cerebrospinal fluid (CSF) have been conducted to determine whether the integrity or activity of neuropeptide-containing systems and their receptors is altered in schizophrenia. Second, studies in which peptides have been administered to schizophrenic patients to evaluate their potential therapeutic use are reviewed. Finally, the effects of peptide receptor antagonists on the symptoms of schizophrenic patients are reviewed.",
author = "Charles Nemeroff and G. Bissette",
year = "1988",
month = "12",
day = "1",
language = "English",
volume = "537",
pages = "273--291",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Neuropeptides, dopamine, and schizophrenia

AU - Nemeroff, Charles

AU - Bissette, G.

PY - 1988/12/1

Y1 - 1988/12/1

N2 - In this paper, three types of evidence for the possible role of neuropeptides in the pathophysiology of schizophrenia are considered. First, studies in postmortem brain tissues and cerebrospinal fluid (CSF) have been conducted to determine whether the integrity or activity of neuropeptide-containing systems and their receptors is altered in schizophrenia. Second, studies in which peptides have been administered to schizophrenic patients to evaluate their potential therapeutic use are reviewed. Finally, the effects of peptide receptor antagonists on the symptoms of schizophrenic patients are reviewed.

AB - In this paper, three types of evidence for the possible role of neuropeptides in the pathophysiology of schizophrenia are considered. First, studies in postmortem brain tissues and cerebrospinal fluid (CSF) have been conducted to determine whether the integrity or activity of neuropeptide-containing systems and their receptors is altered in schizophrenia. Second, studies in which peptides have been administered to schizophrenic patients to evaluate their potential therapeutic use are reviewed. Finally, the effects of peptide receptor antagonists on the symptoms of schizophrenic patients are reviewed.

UR - http://www.scopus.com/inward/record.url?scp=0024262541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024262541&partnerID=8YFLogxK

M3 - Article

VL - 537

SP - 273

EP - 291

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -